GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Singapore Institute of Advanced Medicine Holdings 9G2.SI · SGD

N/A · SGX · 🇸🇬 Singapore

Compare

0.02

+9.52%

Close of 6 Nov 2026, in SGD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Singapore Institute of Advanced Medicine Holdings

Its shares trade on SGX under the ticker 9G2.SI. It has been listed since 16 February 2024. In the fiscal year to 30 June 2026, it reported revenue of SGD 15.7m and a net loss of SGD 23.9m. At that date it held total assets of SGD 132.1m and shareholders' equity of SGD 52.9m.

Singapore Institute of Advanced Medicine Holdings Ltd is a SG-based company operating in industry. Singapore Institute of Advanced Medicine Holdings Pte Ltd is an investment holding company. The firm is a healthcare service provider using advanced technology for early and accurate diagnosis and offering treatments. Its services cater to a range of diseases and health conditions including, but not limited to, cancer, neurodegenerative and cardiovascular disease detection and treatment. The company operates through two segments: Medical Diagnostics and Treatments and Radiation Therapy and Medical Oncology Services. Medical diagnostics and treatments segment cover cancer-related diagnostics and theragnostic treatments; general diagnostics and health screening; and aesthetic services. Radiation Therapy and Medical Oncology Services segment includes cover proton beam therapy, photon radiation therapy, and medical oncology. Its clinic at Biopolis Drive offers services using advanced technology, including radiotherapy services, nuclear medicine, diagnostic imaging and theragnostic services.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
16 Feb 2024

Leadership

Pay as last reported

  • Mr. Tiam Hock KhooIndependent Non-Executive Chairman of the Board
  • Dr. Shih Kien DjengChief Executive Officer, Executive Director, since 2011
  • Mr. Tham Wan YiChief Financial Officer
  • Mr. Seng Lye YeoChief Operating Officer, Executive Director, since 2023
  • Dr. Boon Han KwekChief Medical Officer
  • Ms. Si Ning LimJoint Company Secretary
  • Ms. Woon Hong WeeJoint Company Secretary
  • Mme. Chi Fan ChengNon-Executive Non-Independent Director
  • Dato' Kok Chuan LeeNon-Executive Non-Independent Director
  • Mr. Gurdip SinghNon-Executive Independent Director
  • Ms. Shum SumeiNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Singapore Institute of Advanced Medicine Holdings Ltd operates in the Health Care sector with advanced technology for early diagnosis.
  • The company's Biopolis Drive clinic provides radiotherapy and nuclear medicine services using cutting-edge technology.
  • Medical Diagnostics and Treatments segment covers cancer diagnostics and theragnostic treatments in Singapore.

Weaknesses

  • The company's operations are limited to Singapore with no international expansion mentioned.
  • Singapore Institute of Advanced Medicine Holdings Pte Ltd is a holding company with no direct service operations.
  • The company has no mention of partnerships with major healthcare providers or institutions.

Opportunities

  • The growing demand for cancer diagnostics and theragnostic treatments in Asia presents a significant opportunity.
  • Expansion into neighboring countries like Malaysia and Indonesia could leverage Singapore's healthcare expertise.
  • Increasing focus on neurodegenerative and cardiovascular disease treatments aligns with global health trends.

Threats

  • Rising healthcare costs in Singapore may impact patient affordability and service uptake.
  • Competition from established healthcare providers in the region could challenge market share.
  • Regulatory changes in Singapore's healthcare sector might affect service delivery and operational flexibility.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.